Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline Penetration Into Bone and Joint
2025-524744-36-00Phase 2Authorised
- Sponsor
- CHU Caen Normandie
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxycycline in hip osteoarthritis, sponsored by CHU Caen Normandie. Primary endpoint: Doxycycline penetration in cancellous bone. Planned start Jul 2026; status: authorised.
02
Drugs
doxycycline
03
Conditions
hip osteoarthritis
Beyond the preview
Go deeper on 2025-524744-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524744-36-00.